UNSPSC 51333701: Citicoline

This classification denotes a nootropic agent with the molecular formula C14H25N4O11P2.H+, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 536BQ2JVC7, chemically known as cytidine 5-(trihydrogen pyrophosphate), monoester with choline hydroxide, inner salt but generally known as citicoline, which bears US NIH Compound Identifier 291. European Medicines Agency schedules Citicoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07489MIG.

UNSPSC 51333701 Citicoline is a Commodity code for pharmaceutical products, but the recent state and local procurement activity tagged under it does not reflect citicoline procurement. The single recent opportunity on record — Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026, with response due July 26, 2023 — solicits 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health initiatives. This mismatch suggests either a data-entry error in the opportunity's UNSPSC classification or a jurisdictional tagging practice that does not align with the code's nominal scope. The work being procured is opioid-overdose response equipment and harm-reduction systems, not citicoline (a pharmaceutical cognitive enhancer). State and local governments appear to use this code infrequently, if at all, for its intended commodity category.

The Seminole County opportunity represents the only recent solicitation supporting this code's activity profile. Bids were submitted electronically through the county's e-Procurement Portal, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The contract carries a two-year initial term with an optional one-year renewal, fixed-fee pricing, standard compliance requirements including drug-free workplace certification and E-Verify authorization, and a three-month probationary termination clause. FEMA funding was noted as a potential source, introducing federal environmental compliance overlays. No explicit set-aside designations for disadvantaged enterprises were specified. The lack of additional recent opportunities under this code suggests minimal current state and local procurement activity aligned with citicoline's actual pharmaceutical classification.